Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1996-8-21
|
| pubmed:abstractText |
One of the mechanisms by which multidrug resistance is mediated, is the mdr1 gene product, P-glycooprotein. Immunohistochemistry was performed for 63 osteosarcomas of 54 patients to investigate P-glycoprotein expression using the monoclonal antibody JSB-1. Most of the patients were children or adolescents who had received treatment under the framework of the Cooperative Osteosarcoma Study Group. In addition P-glycoprotein expression was assayed in five growth plates. Of all cases 68.5% stained positive for P-glycoprotein. Cases that had received chemotherapy showed a higher incidence (80.9%) of positive P-glycoprotein immunostaining than cases that had not received chemotherapy (66.6%). No relation could be established between P-glycoprotein expression and the response to chemotherapy, since the majority of P-glycoprotein positive biopsies showed a good response in the surgical specimen after chemotherapy. Furthermore, 42.9% of P-glycoprotein negative biopsies were classified as non-responders in the later surgical specimen. In addition to P-glycoprotein expression in osteosarcomas positive immunostaining was also detected in osteoblasts, osteocytes, osteoclasts as well as in some chondroblasts. The results indicate that P-glycoprotein expression in osteosarcomas also exists prior to chemotherapy and resembles the phenotype of normal bone tissue. However, the determination of P-glycoprotein by using immunohistochemistry in biopsies of osteosarcomas cannot predict the response to chemotherapy.
|
| pubmed:language |
ger
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0172-8113
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
50-5
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8685096-Adolescent,
pubmed-meshheading:8685096-Adult,
pubmed-meshheading:8685096-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8685096-Bone Neoplasms,
pubmed-meshheading:8685096-Bone and Bones,
pubmed-meshheading:8685096-Chemotherapy, Adjuvant,
pubmed-meshheading:8685096-Child,
pubmed-meshheading:8685096-Child, Preschool,
pubmed-meshheading:8685096-Combined Modality Therapy,
pubmed-meshheading:8685096-Drug Resistance, Multiple,
pubmed-meshheading:8685096-Female,
pubmed-meshheading:8685096-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:8685096-Humans,
pubmed-meshheading:8685096-Male,
pubmed-meshheading:8685096-Middle Aged,
pubmed-meshheading:8685096-Osteosarcoma,
pubmed-meshheading:8685096-P-Glycoprotein,
pubmed-meshheading:8685096-Treatment Outcome
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
[P-glycoprotein expression in osteosarcoma].
|
| pubmed:affiliation |
Abteilung Osteopathologie, Pathologisches Institut, Universität, Hamburg.
|
| pubmed:publicationType |
Journal Article,
English Abstract
|